Progenics Pharmaceuticals Sets Third Quarter Financial Results Conference Call
for November 11
TARRYTOWN, N.Y., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) announced that it will host a conference call and webcast
to review third quarter financial results on Monday, November 11, at 8:30 a.m.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 92604931. A live webcast will be
available in the Media Center of the Progenics website, www.progenics.com, and
a replay will be available there for two weeks.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development. Progenics' first-in-class PSMA-targeted
technology platform includes an antibody-drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase 2 clinical trials. Among
other assets in its pipeline of targeted radiotherapy and molecular imaging
compounds is Azedra^™, an ultra-orphan radiotherapy candidate in phase 2 under
an SPA.Progenics' first commercial product, Relistor^® (methylnaltrexone
bromide) for opioid-induced constipation, is partnered with and marketed by
Salix Pharmaceuticals, Inc.Ono Pharmaceutical Co. is developing Relistor in
Japan. Please visit us at www.progenics.com.
CONTACT: Kathleen Fredriksen
Press spacebar to pause and continue. Press esc to stop.